Jiahui Li

Dr. Jiahui Li

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
IIIlkay Idilman
Ilkay Idilman
JLJiahui Li
Jiahui Li
MYMeng Yin
Meng Yin
SVSudhakar Venkatesh
Sudhakar Venkatesh

1 May 2023 in Hepatology
Verified
Journal Article
Open access
JLJiahui Li
Jiahui Li
XLXin Lu
Xin Lu
ZZZheng Zhu
Zheng Zhu
KKKyle J. Kalutkiewicz
Kyle J. Kalutkiewicz
TMTaofic Mounajjed
Taofic Mounajjed
MYMeng Yin
Meng Yin
Background and Aims: The presence of at-risk NASH is associated with an increased risk of cirrhosis and complications. Therefore, noninvasive identification of at-risk NASH with an accurate biomarker is a critical need for pharmacologic therapy. We aim to explore the performance of several magnetic resonance (MR)-based imaging parameters in diagnosing at-risk NASH. Approach and Results: This prospective clinical trial (NCT02565446) includes 104 paired MR examinations and liver biopsies performed in patients with suspected or diagnosed NAFLD. Magnetic resonance elastography-assessed liver stiffness (LS), 6-point Dixon-derived proton density fat fraction (PDFF), and single-point saturation-recovery acquisition-calculated T1 relaxation time were explored. Among all predictors, LS showed the significantly highest accuracy in diagnosing at-risk NASH [AUCLS: 0.89 (0.82, 0.95), AUCPDFF: 0.70 (0.58, 0.81), AUCT1: 0.72 (0.61, 0.82), z-score test z >1.96 for LS vs any of others]. The optimal cutoff value of LS to identify at-risk NASH patients was 3.3 kPa (sensitivity: 79%, specificity: 82%, negative predictive value: 91%), whereas the optimal cutoff value of T1 was 850 ms (sensitivity: 75%, specificity: 63%, and negative predictive value: 87%). PDFF had the highest performance in diagnosing NASH with any fibrosis stage [AUCPDFF: 0.82 (0.72, 0.91), AUCLS: 0.73 (0.63, 0.84), AUCT1: 0.72 (0.61, 0.83), |z| <1.96 for all]. Conclusion: Magnetic resonance elastography-assessed LS alone outperformed PDFF, and T1 in identifying patients with at-risk NASH for therapeutic trials.

Verified
Journal Article
Open access
PDF file
IIIlkay Idilman
Ilkay Idilman
HLHsien Min Low
Hsien Min Low
TGTolga Gidener
Tolga Gidener
KPKenneth Philbrick
Kenneth Philbrick
TMTaofic Mounajjed
Taofic Mounajjed
SVSudhakar Venkatesh
Sudhakar Venkatesh
(1) Purpose: To determine the association between visceral adipose tissue (VAT) and proton density fat fraction (PDFF) with magnetic resonance imaging (MRI), and hepatic steatosis (HS), non-alcoholic steatohepatitis (NASH) and hepatic fibrosis (HF) in patients with known or suspected non-alcoholic fatty liver disease (NAFLD). (2) Methods: 135 subjects that had a liver biopsy performed within 3 months (bariatric cohort) or 1 month (NAFLD cohort) of an MRI exam formed the study group. VAT volume was quantified at L2-L3 level on opposed-phase images with signal intensity-based painting using a semi-quantitative software. Liver PDFF and pancreas PDFF were calculated on fat fraction maps. Liver volume (Lvol) and spleen volume (Svol) were also calculated using a semi-automated 3D volume tool available on PACS. A histological analysis was performed by an expert hepatopathologist blinded to imaging findings. (3) Results: The mean Lvol, Svol, liver PDFF, pancreas PDFF and VAT of the study population were 2492.2 mL, 381.6 mL, 13.2%, 12.7% and 120.6 mL, respectively. VAT showed moderate correlation with liver PDFF (r = 0.41, p < 0.001) and weak correlation with Lvol (r = 0.38, p < 0.001), Svol (r = 0.20, p = 0.025) and pancreas PDFF (rs = 0.29, p = 0.001). VAT, Lvol and liver PDFF were significantly higher in patients with HS (p < 0.001), NASH (p < 0.05) and HF (p < 0.05). VAT was also significantly higher in the presence of lobular inflammation (p = 0.019) and hepatocyte ballooning (p = 0.001). The cut-off VAT volumes for predicting HS, NASH and HF were 101.8 mL (AUC, 0.7), 111.8 mL (AUC, 0.64) and 111.6 mL (AUC, 0.66), respectively. (4) Conclusion: The MRI determined VAT can be used for predicting the presence of HS, NASH and HF in patients with known or suspected NAFLD.

1 April 2025 in Radiology
Verified
Journal Article
Closed access
HWHao Wu
Hao Wu
ZZZheng Zhu
Zheng Zhu
JLJiahui Li
Jiahui Li
CQCaixin Qiu
Caixin Qiu
PXPeng Xu
Peng Xu
MYMeng Yin
Meng Yin
Spatial heterogeneity of liver viscoelasticity, measured at three-dimensional vector MR elastography, positively correlated with metabolic dysfunction–associated steatotic liver disease progression.

18 March 2025 in Hepatology
Verified
Journal Article
Closed access
AAAlina M. Allen
Alina M. Allen
WKW. Ray Kim
W. Ray Kim
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri
RCRachel Canning
Rachel Canning
Fang-Shu OuFang-Shu Ou
Fang-Shu Ou
JLJeffrey Lazarus
Jeffrey Lazarus
Screening for diseases can have psychological impacts, such as anxiety, and requires acceptability from the population to be effective. This study examined the perspectives on the benefits and harms of screening for metabolic dysfunction-associated steatotic liver disease (MASLD) among the general population to optimize screening practices. A survey was sent to participants enrolled between 2020-2024 in a prospective MASLD screening study in Olmsted County, MN. The survey assessed participants’ perceived anxiety, stigma, quality of life, preferred screening methods, financial concerns, and lifestyle impacts following screening and diagnosis. Of the 461 participants, 342 (74%) completed the survey. Overall, 14% of participants reported screening-related anxiety and 14% were concerned about disclosing a potential MASLD diagnosis to others. Among those without a MASLD diagnosis, 99% felt reassured about their liver health, 48% reported an improved quality of life, and 25% made lifestyle changes pertaining to their diet, alcohol use, and physical activity. Of the 77 participants diagnosed with MASLD, 52% experienced some anxiety about their new diagnosis; however, 95% and 97% considered it important to receive an early MASLD diagnosis to mitigate the risk for cirrhosis and cardiovascular disease, respectively. Notably, 79% of diagnosed participants found the diagnosis beneficial in adopting healthier habits, with 30% achieving a >10% weight loss after screening. Conclusion: This population-based survey demonstrates that the perceived benefits of proactive MASLD screening, such as increased awareness, lifestyle changes, and early diagnosis, outweigh the harms. These findings highlight the importance of early screening through patient-centered protocols to improve health outcomes. Export

4 March 2025 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
PDF file
JLJiahui Li
Jiahui Li
MOMarzanna Obrzut
Marzanna Obrzut
JCJie Chen
Jie Chen
BDBogdan Dzyubak
Bogdan Dzyubak
KGKevin J. Glaser
Kevin J. Glaser
MYMeng Yin
Meng Yin